alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
H. R. 7385 

One Hundred Eighteenth Congress 

of the 

United States of America 

AT THE SECOND SESSION 

Begun and held at the City of Washington on Wednesday, 

the third day of January, two thousand and twenty-four 

An Act 

To designate the facility of the United States Postal Service located at 29 Franklin 

Street in Petersburg, Virginia, as the ‘‘John Mercer Langston Post Office Building’’. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. JOHN MERCER LANGSTON POST OFFICE BUILDING. 

(a) DESIGNATION.—The facility of the United States Postal 

Service located at 29 Franklin Street in Petersburg, Virginia, shall 

be known and designated as the ‘‘John Mercer Langston Post Office 

Building’’. 

(b) REFERENCES.—Any reference in a law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘John Mercer Langston Post Office Building’’. 

Speaker of the House of Representatives. 

Vice President of the United States and

President of the Senate.
§ 182.1778 Sodium phosphate. ( a ) *Product.* Sodium phosphate (mono-, di-, and tribasic).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing practice.
§ 520.90b Ampicillin capsules. ( a ) *Specifications.* Each capsule contains ampicillin trihydrate equivalent to 125, 250, or 500 milligrams of ampicillin.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* 5 to 10 milligrams per pound of body weight two or three times daily. In severe or acute conditions, 10 milligrams per pound of body weight, three times daily. Administer 1 to 2 hours prior to feeding.
( ii ) *Indications for use.* Treatment against strains of gram-negative and gram-positive organisms sensitive to ampicillin and associated with respiratory tract infections (tracheobronchitis and tonsillitis); urinary tract infections (cystitis); bacterial gastroenteritis; generalized infections (septicemia) associated with abscesses, lacerations, and wounds; and bacterial dermatitis.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Cats* — ( i ) *Amount.* 10 to 30 milligrams per pound of body weight or three times daily. Administer 1 to 2 hours prior to feeding.
( ii ) *Indications for use.* Treatment against strains of gram-negative and gram-positive organisms sensitive to ampicillin and associated with respiratory tract infections (bacterial pneumonia); urinary tract infections (cystitis); and generalized infections (septicemia) associated with abscesses, lacerations, and wounds.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37321, Aug. 18, 1992, as amended at 58 FR 61016, Nov. 19, 1993; 79 FR 28818, May 20, 2014. Redesignated at 85 FR 18118, Apr. 1, 2020]
To: Alexis McKittrick/DC/USEPA/US@EPA From: David Isaacs <DIsaacs@sia-online.org>

Date: 11/15/2012 04:28PM Cc: "Hsi-An Kwong (Hsi-An.Kwong@sematec h.org)" <Hsi-An.Kwong@sematech.org>, "Laurie.Beu@ismi.sematech.org" <Laurie.Beu@is mi.sematech.org>, "Rajguru, Sanjay (ISMI)" <sanjay.rajguru@ismi.sematech.org> Subject: FW: EPA docket - IS MI copyright materials

Alexis - as a follow-up to our phone call today, please see the message below from ISMI regarding the copyrighted materials in the EPA docket. I hope this meets you needs, and please let me know if you need any additional assistance.

David

From: Kwong, Hsi-An (ISMI) [ mailto:hsi-an.kwong@ismi.sematech.org ] Sent: Thursday, November 15, 2012 4:13 PM

To: David Isaacs Cc: Beu, Laurie (ISMI); Rajguru, Sanjay (ISMI) Subject: RE: EPA docket - ISMI copyright materials

Dear David:

Per EPA's request, ISMI grants permission to the EPA to waive the ISMI copyright disclaimer of the following documents:

- EPA-HQ-OAR-2011-0028-0052 - "ISMI. Comparison of Fourier Transform Infrared (FTIR) and Quadrupole Mass Spectroscopy (QMS) Methods for Determining POU Abatement System Effluent
Flow. October 30, 2010"

- EPA-HQ-OAR-2011-0028-0054 - "Beu, L. Reduction of Perfluorocarbon (PFC) Emissions: 2005 State-of-the-Technology Report, TT#05104693A-ENG, International SEMATECH Manufacturing
Initiative (ISMI), December 2005"

- EPA-HQ-OAR-2011-0028-0074 - "Report to EPA on Etch Factor Proposal for Fab GHG Emissions Reporting. February 28, 2012"

- Attachment to EPA-HQ-OAR-2011-0028-0086 - "SIA ISMI Presentation of Etch Alternative to EPA 11-17-11", titled "Additions & Corrections ISMI-SIA Alternative to Recipe-Specific Testing of 17Nov11". (The "SIA ISMI Presentation of Etch Alternative to EPA 11-17-11" document was previously released from copyright, but the attachment was not.)

It appears to me that the correct Technology Report number for the second document listed above should have been TT#05104693A-ENG (missing a number "3" in the original email). I

have corrected it as indicated.

Please contact me if you have questions or need additional clarification.

Best regards,

Hsi-An

Hsi-An Kwong, P.E.

ESH Program Manager International SEMATECH Manufacturing Initiative 257 Fuller Road, Suite 2200 Albany, New York 12203
Phone: (518) 649-1265 hsi-an.kwong@ismi.sematech.org< mailto:hsi-an.kwong@ismi.sematech.org >
#### § 520.1242 Levamisole.
###### Editorial Note on Part 314

#### Editorial Note:

Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.

#### § 314.640 Promotional materials.

For drug products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit to the agency for consideration during the preapproval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval. After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.
§ 333.280 Professional labeling. The labeling provided to health professionals (but not to the general public) may contain the following additional indication: ( a ) *For products containing haloprogin or miconazole nitrate identified in § 333.210 (a) and (c) .* “For the treatment of superficial skin infections caused by yeast (*Candida albicans*).”
( b ) [Reserved]
Exhibit 10.2(b)


   Schedule of Secured Convertible Note (refinancings after October 31, 2005)
Issued by NCT Group, Inc. to Carole Salkind on July 31, 2006 and August 2, 2006



    Issue Date       Due Date          Principal           Conversion Price
    ----------       --------          ---------           ----------------
     07/31/06        01/31/07          $800,000         Greater of: (i) $0.0019;
                                                        or (ii) the par value of
                                                        NCT Group, Inc.
                                                        common stock on the
                                                        date of conversion

     08/02/06        02/02/07          $800,000         Greater of: (i) $0.0019;
                                                        or (ii) the par value of
                                                        NCT Group, Inc.
                                                        common stock on the
                                                        date of conversion
EXHIBIT 32.2


                                  CERTIFICATION
                       PURSUANT TO 18 U.S.C. SECTION 1350,
           AS ADOPTED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


         I, Stephen L. Brown,  as Chief  Executive  Officer of Franklin  Capital
Corporation (the "COMPANY") certify,  pursuant to 18 U.S.C. ss. 1350, as adopted
by Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

         (1) the  accompanying  Form 10-Q report for the period  ending June 30,
2003 as filed with the U.S.  Securities and Exchange  Commission  (the "REPORT")
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended; and

         (2) the  information  contained in the Report fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.

Dated:  August 12, 2003                              /s/ Hiram M. Lazar
                                                     ------------------
                                                     Hiram M. Lazar
                                                     Chief Financial Officer

A signed  original of this  written  statement  required by Section 906 has been
provided  to  Franklin  Capital  Corporation  and will be  retained  by Franklin
Capital  Corporation and furnished to the Securities and Exchange  Commission or
its staff upon request.
---

---

Exhibit 14.3

CONSENT
OF INDEPENDENT PUBLIC ACCOUNTING FIRM

We consent to the incorporation by
reference in the Registration Statements of NUR Macroprinters Ltd. on Form S-8 (File Nos.
333-102288 and 333-92491) filed with the Securities and Exchange Commission pertaining to
the 1995 Israel Stock Option Plan, the 1997 Stock Option Plan, the 1998 Non-Employee
Director Share Option Plan and the 2000 Stock Option Plan of NUR Macroprinters Ltd. and
Form F-3 (File Nos. 333-115826, 333-114428, 333-47842 and 333-92493) of our report dated
June 1, 2005 relating to the financial statements of NUR Japan Ltd. for the year ended
December 31, 2003 with respect to the Consolidated Financial Statements of NUR
Macroprinters Ltd., included in its Amendment no. 1 to the annual report on Form 20-F for
the year ended December 31, 2004 filed with the United States Securities and Exchange
Commission.

/s/ Grant Thornton Tokyo ASG
Tokyo, Japan
March 9, 2006



---

---
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                         521,200
<SECURITIES>                                         0
<RECEIVABLES>                                   83,011
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      11,578,221
<DEPRECIATION>                               4,926,542
<TOTAL-ASSETS>                              12,554,710
<CURRENT-LIABILITIES>                          773,110
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   1,316,418
<TOTAL-LIABILITY-AND-EQUITY>                12,554,710
<SALES>                                      1,229,793
<TOTAL-REVENUES>                             1,229,793
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             1,136,536
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             217,844
<INCOME-PRETAX>                              (121,404)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (121,404)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
April 24, 2009 

Tony Britten, Team Leader 

Emergency Response Team 

U.S. EPA Office of Pesticide Programs (7505P) 

Document Processing Desk (EMEX) 

One Potomac Yard, Room S4900 

2777 Crystal Drive 

Arlington, VA 22202 

Dear Mr. Britten, 

 

Wisconsin Department of Agriculture, Trade & Consumer Protection (WDATCP) requests a specific emergency exemption 

under the provisions of Section 18 of the Federal Insecticide, Fungicide and Rodenticide Act, as amended, for use of 

spirotetramat formulated as the product MoventoTM (EPA Reg. No. 264-1050) on dry bulb onions to control onion thrips, 

and incorporates by reference any supplemental supporting information in a similar request submitted by the Colorado 

Department of Agriculture. This is the first year that WDATCP has requested this use. 

Please note Dr. Russell Groves’ discussion on page 5 regarding the need to have a sufficient number of effective products 

with different modes of action. 

 

Based on the Section 3 product label, the active ingredient has environmental properties (mobility and runoff potential) and 

ecotoxicity (acute toxicity to aquatic invertebrates) that may be of concern for groundwater and/or surface water. However, 

Dr. Russell Groves of University of Wisconsin-Madison reports that almost the entire dry bulb onion crop in Wisconsin is 

grown on muck soils and that very few operators, which are small, grow onions for fresh market product on mineral soils. 

We note general concerns about potential impacts on endangered species based on the product’s toxicity to aquatic 

invertebrates, either directly (mussels) or indirectly (birds that depend on aquatic invertebrates as a food source); however, 

these species are in discrete locations, a maximum of 10 oz product/acre would be applied, and the environmental hazards 

section of the Section 3 label does outline precautions designed to prevent drift and runoff and to protect aquatic organisms. 

The active ingredient has ecotoxicity (toxicity to honey bee larvae) that may be of concern for bees. However, Dr. Groves 

reports that onions don’t set seed in Wisconsin -- Wisconsin growers typically influence the crop to grow vegetatively to 

ensure energy goes into bulbing rather than seed. In the absence of blooms we would not expect adult honey bees to visit 

onion plants and, therefore, would not expect exposure via pollen/nectar to pose an issue for honey bee larvae. 

If you have any questions regarding this application, please let me know. 

Sincerely, 

Matt Sunseri 

Pesticide/IPM Program Specialist 

Wisconsin Department of Agriculture, Trade and Consumer Protection 

2811 Agriculture Drive 

PO Box 8911 

Madison, WI 53708-8911 

(608) 224-4547 

matthew.sunseri@wisconsin.gov
<TABLE> <S> <C>

<ARTICLE>     9
<LEGEND>
    The schedule contains summary financial information extracted
    from the consolidated balance sheet as of September 30, 1995 and
    consolidated statements of income for the nine months ended
    September 30, 1995.
</LEGEND>
<MULTIPLIER>                         1,000
       
<S>                                  <C>
<PERIOD-TYPE>                        9-MOS
<FISCAL-YEAR-END>                    DEC-31-1995
<PERIOD-END>                         SEP-30-1995
<CASH>                                    23,813
<INT-BEARING-DEPOSITS>                     3,538
<FED-FUNDS-SOLD>                               0
<TRADING-ASSETS>                               0
<INVESTMENTS-HELD-FOR-SALE>              320,974
<INVESTMENTS-CARRYING>                         0
<INVESTMENTS-MARKET>                           0
<LOANS>                                1,065,415
<ALLOWANCE>                                5,061
<TOTAL-ASSETS>                         1,533,944
<DEPOSITS>                               903,781
<SHORT-TERM>                             347,433
<LIABILITIES-OTHER>                       52,032
<LONG-TERM>                              104,668
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                  75,368
<OTHER-SE>                                49,760
<TOTAL-LIABILITIES-AND-EQUITY>         1,533,944
<INTEREST-LOAN>                           51,084
<INTEREST-INVEST>                         19,473
<INTEREST-OTHER>                               0
<INTEREST-TOTAL>                          70,557
<INTEREST-DEPOSIT>                        28,629
<INTEREST-EXPENSE>                        47,874
<INTEREST-INCOME-NET>                     22,683
<LOAN-LOSSES>                                 24
<SECURITIES-GAINS>                         1,054
<EXPENSE-OTHER>                           59,292
<INCOME-PRETAX>                           19,260
<INCOME-PRE-EXTRAORDINARY>                19,260
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                              12,244
<EPS-PRIMARY>                               0.79
<EPS-DILUTED>                               0.79
<YIELD-ACTUAL>                              2.39
<LOANS-NON>                                  865
<LOANS-PAST>                                 491
<LOANS-TROUBLED>                             794
<LOANS-PROBLEM>                                0
<ALLOWANCE-OPEN>                           5,544
<CHARGE-OFFS>                                731
<RECOVERIES>                                 224
<ALLOWANCE-CLOSE>                          5,061
<ALLOWANCE-DOMESTIC>                       2,670
<ALLOWANCE-FOREIGN>                            0
<ALLOWANCE-UNALLOCATED>                    2,391
        

</TABLE>
<PAGE>   1


                                                                    EXHIBIT 23.1

                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

We consent to the incorporation by reference in this Registration Statement of
Getty Images, Inc. on Form S-3 of our report dated March 31, 1999 of our audits
of the consolidated financial statements and financial statement schedules of
Getty Images, Inc. and subsidiaries and of its predecessor, Getty Communications
plc and subsidiaries, appearing in the Annual Report on Form 10-K of Getty
Images, Inc. We also consent to the reference to our firm under the caption
"Experts".



                                        /s/ PricewaterhouseCoopers


PricewaterhouseCoopers
London
August 12, 1999
<PAGE>   1

                       [THE LOEWEN GROUP INC. LETTERHEAD]


                              FOR IMMEDIATE RELEASE


LOEWEN GROUP ANNOUNCES CASH DIVIDEND ON PREFERRED SHARES

VANCOUVER, BC, September 11, 1998

The Loewen Group Inc. announced today that the scheduled quarterly cash dividend
of Cdn $0.375 per share on the Company's 6% Cumulative Redeemable Convertible
First Preferred Shares, Series C has been declared payable on October 1, 1998 to
shareholders of record on September 23, 1998. It is expected that the preferred
shares will begin trading ex-dividend on September 21, 1998.

The Loewen Group Inc. is the second largest funeral home and cemetery operator
in North America. The Company employs approximately 16,000 people and owns or
operates more than 1,100 funeral homes and over 500 cemeteries across the United
States, Canada and the United Kingdom. Over 90 per cent of the Company's revenue
is derived from the United States.


The Loewen Group's website is located at http://www.loewengroup.com

                                     - 30 -
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                                <C>
<PERIOD-TYPE>                      3-MOS
<FISCAL-YEAR-END>                                   MAY-31-1999
<PERIOD-END>                                        Feb-27-1999
<CASH>                                                                  11,401
<SECURITIES>                                                                 0
<RECEIVABLES>                                                          657,151
<ALLOWANCES>                                                                 0
<INVENTORY>                                                            432,406
<CURRENT-ASSETS>                                                     1,137,507
<PP&E>                                                               1,620,391
<DEPRECIATION>                                                          82,601
<TOTAL-ASSETS>                                                       2,757,898
<CURRENT-LIABILITIES>                                                4,525,975
<BONDS>                                                                      0
<PREFERRED-MANDATORY>                                                        0
<PREFERRED>                                                                  0
<COMMON>                                                                15,451
<OTHER-SE>                                                           2,903,973
<TOTAL-LIABILITY-AND-EQUITY>                                         2,748,150
<SALES>                                                              2,491,476
<TOTAL-REVENUES>                                                     2,491,476
<CGS>                                                                2,196,298
<TOTAL-COSTS>                                                        3,343,817
<OTHER-EXPENSES>                                                        (9,186)
<LOSS-PROVISION>                                                             0
<INTEREST-EXPENSE>                                                      61,325
<INCOME-PRETAX>                                                       (909,002)
<INCOME-TAX>                                                                 0
<INCOME-CONTINUING>                                                   (909,002)
<DISCONTINUED>                                                               0
<EXTRAORDINARY>                                                              0
<CHANGES>                                                                    0
<NET-INCOME>                                                          (909,002)
<EPS-PRIMARY>                                                            (0.59)
<EPS-DILUTED>                                                            (0.59)
        

</TABLE>
MEMORANDUM

DATE: January 30, 2012

SUBJECT: Telephone Conference Call with Office of Management and Budget (OMB) on 

January 27, 2012

FROM: EPA OAQPS

TO: Secondary Aluminum Production Risk and Technology Review Docket

(EPA EPA-HQ-OAR-2010-0544)

A telephone conference call was held on January 27, 2012, to discuss OMB comments on 

proposed changes to the Secondary Aluminum Production NESHAP related to the Risk and 

Technology Review for this source category. OMB requested that: a footnote be added to the 

preamble describing how facilities were selected to receive the nine-company testing ICR; the 

word “multiplication” be replaced with “default” to describe risk associated with short-term 

acute exposures; the first sentence of the cost impacts discussion be deleted; and the paragraph 

on economic impacts be revised consistent with that from the primary aluminum NESHAP 

rulemaking preamble.